11 completed, 5 unknown, 3 recruiting, 1 not yet recruiting. 12 Phase 2, 6 Phase 3, 4 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 7, Unknown 4, Recruiting 1 |
| Phase 3 | 6 | Unknown 4, Completed 2 |
| Phase 1 | 4 | Completed 3, Not yet recruiting 1 |
| Not applicable | 1 | Completed 1 |
Follow Leishmaniasis, Mucocutaneous: new trials by email Literature Review of Leishmaniasis, Mucocutaneous trials Research Report on Leishmaniasis, Mucocutaneous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pilot Study: Miltefosine Gel (G-MTF) in Patients With Cutaneous Leishmaniasis MILTEFOSINE gel - Cutaneous Leishmaniasis, Cutaneous Leishmaniasis, American | Phase 1 | Not yet recruiting | Universidad Industrial de Santander | 15 | 2026-01-01 | 2025-09-08 |
| Treatment of Bolivian L Braziliensis Mucosal Leishmaniasis With Inhaled Pentamidine Plus Oral Miltefosine Miltefosine Oral Capsule - Mucosal Leishmaniasis | Phase 2 | Recruiting | Fundacion Nacional de Dermatologia | 30 | 2025-02-04 | 2025-02-26 |
| LEISH-PED: Study on Leishmaniasis in Children Leishmania Infantum Disease, Leishmaniasis, Visceral | Recruiting | Meyer Children's Hospital IRCCS | 200 | 2025-01-30 | 2026-04-01 | |
| Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis Oral tofacitinib, Parenteral meglumine antimoniate - Cutaneous Leishmaniasis, American | Phase 2 / Phase 3 | Unknown | Hospital Universitário Professor Edgard Santos | 22 | 2023-10-01 | 2023-08-25 |
| Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly Miltefosine 50mg, Pentoxifylline 400mg, Liposomal Amphotericin B - Leishmaniasis; Brazilian, Leishmaniasis, Mucocutaneous | Phase 2 / Phase 3 | Unknown | University of Brasilia | 100 | 2022-06-22 | 2023-09-15 |
| Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients 18-Methoxycoronaridine, Glucantime - Leishmaniasis; American, Cutaneous, Drug Side Effect | Phase 2 | Unknown | Infan Industria Quimica Farmaceutica Nacional | 52 | 2021-05-01 | 2020-03-19 |
| Treatment of Mucosal Bolivian Leishmaniasis Group 1: Miltefosine, Group 2: Pentavalent Antimony, Group 3: Liposomal amphotericin B - Mucosal Leishmaniasis | Phase 3 | Unknown | Fundacion Nacional de Dermatologia | 120 | 2021-04-01 | 2024-03-05 |
| Feasibility and Usability of Mobile Applications for Monitoring Cutaneous Leishmaniasis Treatment in Colombia Community based strategy to follow-up pactientes with Cutaneous Leishmaniasis - Cutaneous Leishmaniasis, American | Not applicable | Completed | Centro Internacional de Entrenamiento e Investigaciones Médicas | 105 | 2020-03-01 | 2022-09-09 |
| Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly Liposomal amphotericin B (AmBisome®) - Cutaneous Leishmaniasis, American | Phase 1 / Phase 2 | Completed | Hospital Universitário Professor Edgard Santos | 28 | 2019-03-01 | 2024-06-07 |
| Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis Miltefosine and Paromomycin, miltefosine, paromomycin - Cutaneous Leishmaniasis, American | Phase 2 / Phase 3 | Completed | Fundacion Nacional de Dermatologia | 120 | 2019-02-01 | 2021-02-02 |
| Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis. Sm29 Protein, Schistosoma Mansoni, Pentavalent antimony (Sbv) - Cutaneous Leishmaniasis, American | Phase 1 / Phase 2 | Completed | Hospital Universitário Professor Edgard Santos | 20 | 2019-01-17 | 2023-08-21 |
| Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia Paromomycin Sulfate, Pentamidine Isethionate, Placebo - Leishmaniasis, Cutaneous, Leishmania Braziliensis Complex | Phase 2 / Phase 3 | Completed | Fundacion Nacional de Dermatologia | 80 | 2017-04-15 | 2021-02-02 |
| Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis Miltefosine - Mucocutaneous Leishmaniasis | Completed | Knight Therapeutics (USA) Inc | 42 | 2015-12-01 | 2020-09-04 | |
| Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis Miltefosine - Mucocutaneous Leishmaniasis | Completed | Knight Therapeutics (USA) Inc | 55 | 2015-07-01 | 2019-03-04 | |
| Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis Immucillin DI4G, Meglumine antimoniate - Leishmaniasis, Leishmaniasis, Cutaneous | Phase 2 | Completed | Hospital Universitário Professor Edgard Santos | 50 | 2014-12-01 | 2017-09-26 |
| Miltefosine to Treat Mucocutaneous Leishmaniasis Miltefosine - Mucosal Leishmaniasis, Cutaneous Leishmaniasis | Phase 2 | Completed | Knight Therapeutics (USA) Inc | 4 | 2010-05-01 | 2020-09-30 |
| Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis Miltefosine, Standard Treatment Meglumine antimoniate - Leishmaniasis, Leishmaniasis, Mucocutaneous | Phase 2 | Completed | Brasilia University Hospital | 40 | 2009-07-01 | 2015-06-09 |
| Low Antimonial Dosage in American Mucosal Leishmaniasis Meglumine antimoniate - Mucosal Leishmaniasis, Mucocutaneous Leishmaniasis | Phase 2 / Phase 3 | Unknown | Oswaldo Cruz Foundation | 76 | 2008-10-01 | 2018-07-12 |
| Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis Leish-111f + MPL-SE vaccine - Leishmaniasis, Mucocutaneous | Phase 1 | Completed | Access to Advanced Health Institute (AAHI) | 48 | 2004-07-01 | 2007-02-15 |
| Diagnosis and Treatment of Leishmania Infections Kinetoplastid, Skin Diseases, Parasitic | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 400 | 2001-11-30 | 2026-10-29 |
Showing 20 of 21. Sign in to see all of them.
Leishmaniasis (10) · Leishmaniasis, Cutaneous (10) · Leishmaniasis, Visceral (2) · Drug-Related Side Effects and Adverse Reactions (1) · Parasitic Diseases (1) · Skin Diseases, Parasitic (1)
Euglenozoa Infections (21) · Infections (21) · Protozoan Infections (21) · Skin Diseases (21) · Skin Diseases, Infectious (21) · Skin and Connective Tissue Diseases (21) · Vector Borne Diseases (21) · Parasitic Diseases (20) · Skin Diseases, Parasitic (20) · Leishmaniasis (11) · Leishmaniasis, Cutaneous (11) · Chemically-Induced Disorders (1)
miltefosine (8) · Meglumine Antimoniate (3) · Paromomycin (2) · liposomal amphotericin B (2) · 18-methoxycoronaridine (1) · Antimony Sodium Gluconate (1) · Pentamidine (1) · Pentoxifylline (1) · Sm29 protein, Schistosoma mansoni (1) · tofacitinib (1)
Fundacion Nacional de Dermatologia (4) · Hospital Universitário Professor Edgard Santos (4) · Knight Therapeutics (USA) Inc (3) · Access to Advanced Health Institute (AAHI) (1) · Brasilia University Hospital (1) · Centro Internacional de Entrenamiento e Investigaciones Médicas (1) · Infan Industria Quimica Farmaceutica Nacional (1) · Meyer Children's Hospital IRCCS (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Oswaldo Cruz Foundation (1) · Universidad Industrial de Santander (1) · University of Brasilia (1) · University of California, San Francisco (1)
Brazil (7) · Bolivia (6) · United States (3) · Colombia (2) · Italy (1) · Peru (1)
Jaime Soto, MD (2) · Alejandro Llanos-Cuentas, MD (1) · Armando O. Schubach, MD, PhD (1) · Brian Schwartz, MD (1) · Cristian Blanco, PhD (1) · Edgar M Carvalho, MD, PhD (1) · Elise M O'Connell, M.D. (1) · Franco M Piazza, MD, MPh (1) · Jonathan Berman, MD (1) · Juliana SF Silva, MD (1) · Kanade Shinkai, MD (1) · Paulo RL Machado, MD, PhD (1)
PMID 11353640, PMID 20851080, PMID 27927991, PMID 30260376, PMID 30815688, PMID 36395328, PMID 39147194